Soligenix, Inc. (SNGX) – PRNewswire
-
Soligenix Announces Pricing of $4.75 Million Public Offering
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
-
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
-
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
-
Soligenix to Present at The Microcap Conference
-
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
-
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
-
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
-
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
-
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
-
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
-
Soligenix to Present at The ThinkEquity Conference
-
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
-
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
-
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
-
Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis
-
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
-
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
-
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Announces Closing of $8.5 Million Public Offering
-
Soligenix Announces Pricing of $8.5 Million Public Offering
-
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
-
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Provides Regulatory Update on HyBryte™
-
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
-
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
-
Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Announces Reverse Stock Split
-
Soligenix Invited to Present at the Virtual Investor Summit Event
-
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
-
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
-
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
-
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
-
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
-
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
-
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
-
Soligenix Announces Formation of Psoriasis Medical Advisory Board
-
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
-
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
-
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
Back to SNGX Stock Lookup
